SCHEMBL28207266

SCHEMBL28207266

O=C[CH]NC(=O)OCc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
NPC1 O15118 2/20 0.54
POLB P06746 2/20 0.54
RAB9A P51151 2/20 0.54
KMT2A Q03164 2/20 0.54
MEN1 O00255 1/20 0.54
MAPT P10636 1/20 0.54
LMNA P02545 1/20 0.53
CA12 O43570 2/20 0.51
CA1 P00915 2/20 0.51
CA2 P00918 2/20 0.51
CA9 Q16790 2/20 0.51
HTT P42858 1/20 0.50
MIF P14174 1/20 0.49
HCAR2 Q8TDS4 1/20 0.49
MAPK1 P28482 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
SLC6A2 P23975 1/20 0.49
SLC6A3 Q01959 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8775648 0.86 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2NPC1POLBRAB9A
SCHEMBL1557396 0.85 TGM2 (0.54) ALDH1A1SMN1; SMN2NPC1POLBRAB9A
SCHEMBL7448378 0.81 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2NPC1POLBRAB9A
SCHEMBL3928127 0.81 LMNA (0.56) ALDH1A1SMN1; SMN2NPC1POLBRAB9A
SCHEMBL483306 0.81 TGM2 (0.56) ALDH1A1SMN1; SMN2NPC1POLBRAB9A
SCHEMBL14855359 0.81 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2NPC1POLBRAB9A
SCHEMBL645150 0.81 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2NPC1POLBRAB9A
SCHEMBL4291030 0.79 ALDH1A1 (0.54) ALDH1A1SMN1; SMN2NPC1POLBRAB9A
SCHEMBL1415895 0.79 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2NPC1POLBRAB9A
SCHEMBL2295789 0.79 CA12 (0.66) ALDH1A1SMN1; SMN2NPC1POLBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104302655-B Sterol derivative and and its for treat involve conversion astroglia disease or treat malignant hematologic disease purposes 倍塔因诺弗公司 2018-04-03 CN disclosed